- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02115100
Treatment of Atrial Fibrillation in Patients by Pulmonary Vein Isolation in Combination With Renal Denervation or Pulmonary Vein Isolation Only (ASAF)
Treatment of Atrial Fibrillation in Patients With High Sympathetic Activity by Pulmonary Vein Isolation in Combination With Renal Denervation or Pulmonary Vein Isolation Only; an International Randomized, Controlled Trial
Prospective, randomized, controlled, multicenter, international clinical trial. The study population consist of patients with paroxysmal or persistent atrial fibrillation with out range hypertension or signs of sympathetic overdrive. Patient will be randomized into one of the following two groups.
group 1 : patients will undergo pulmonary vein isolation, group 2: Patients will undergo pulmonary vein isolation and renal artery denervation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The target group of patients are subjects ages <65 years, with paroxysmal or persistent atrial fibrillation, who have out of range hypertension (systolic >140 mmHg or >130/80 mmHg in diabetics and patients with chronic renal disease) or signs of sympathetic overdrive. Patients should use at least 2 anti-hypertensive's or should be intolerant for antihypertensive medication.
Atrial fibrillation terminology: If atrial fibrillation recurs more than once but terminates spontaneously within seven days, the term paroxysmal AF is used. This is also used when the episode is less than 48 hours in duration and is terminated with electrical or pharmacological cardioversion. Persistent AF is defined as recurrent AF that is sustained for more than seven days. A patient that is electrically or pharmacologically cardioverted after more than two days is also diagnosed with persistent AF.
After the exclusion of apparent secondary causes of hypertension, patients will be randomized to one of the following interventional treatments:
First arm: PVI (69 patients) Second arm: PVI + RDN (69 patients)
The patient will be treated under conscious sedation or general anesthesia. The control group will consist of patients who undergo PVI alone. The study will be a randomized, controlled trial. The follow up period will be up to one year after the interventional therapy. Patients will be treated clinically and will have regular follow-up at the outpatient clinic of the hospital at which they were treated. If patients receive continuous loop recorders for cardiac rhythm monitoring, this data will be used for the study. The other patients will undergo Holter ECG monitoring at regular intervals during follow-up (at 3, 6 and 12 months after the interventional treatment). During follow-up, the first 3 months after the interventional treatment will be a blanking period, as is common in the ablative therapy of AF (ablations points need to heal, and paroxysms of AF in this period are not associated with therapy failure).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Maastricht, Netherlands
- MUMC
-
Nijmegen, Netherlands
- Radboudumc
-
-
Overijssel
-
Zwolle, Overijssel, Netherlands, 8313AB
- Isala hospital
-
-
-
-
-
Barcelona, Spain
- Hospital Clínic de Barcelona
-
Madrid, Spain
- Hospital Universitario 12 de Octubre
-
Madrid, Spain
- Hospital Puerta de Hierro
-
Madrid, Spain
- Hospital Fundación Jimenez Díaz
-
Malaga, Spain
- Hospital Universitario Virgen de la Victoria
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient is willing and able to comply with the protocol and has provided written informed consent.
- The patient falls within the target group resistant hypertension or sympathetic overdrive
- Patient is an acceptable candidate for renal denervation treatment
- Patient is < 65 year of age
Exclusion Criteria:
- Documented left atrial diameter on trans thoracic echocardiography (PLAX > 4.5 cm).
- Contraindication to chronic anticoagulation therapy or heparin.
- Previous left heart ablation procedure for AF (atrial fibrillation).
- Acute coronary syndrome, cardiac surgery, PCI (percutaneous coronary intervention)or stroke within 3 months prior to enrollment.
- Untreated hypothyroidism or hyperthyroidism.
- More than grade 1/3 valvular regurgitation and/or significant valve stenosis (modest or severe).
- LVEF (Left ventricular function) <45% and/or grade 3/4 diastolic dysfunction.
- Enrollment in another investigational drug or device study.
- Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertile age.
- Mental or physical inability to participate in the study.
- Planned cardiovascular intervention.
- Life expectancy ≤ 12 months.
Renal artery stenosis >50% of the arterial lumen, or renal artery lumen
≤3 mm.
- Dual or triple ipsilateral renal artery ostia.
- Obvious secondary cause of hypertension.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: pulmonary vein+renal artery denervation
Procedure: pulmonary vein and renal artery denervation
|
Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only
Other Names:
|
ACTIVE_COMPARATOR: Pulmonary vein isolation
Procedure: Pulmonary vein isolation
|
Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to first detection of atrial fibrillation > 30 seconds, with the monitoring period starting 3 months after the intervention.
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A-fib burden during follow-up, expressed in % of the monitoring period, in patients with continuous rhythm monitoring.
Time Frame: 12 months
|
The monitoring starts after 3 months
|
12 months
|
Blood pressure after intervention, and change in blood pressure compared to measurement before the intervention
Time Frame: 3/6/12 months
|
3/6/12 months
|
|
Blood pressure and heart rate response changes induced by exercise testing
Time Frame: 12 months
|
12 months
|
|
Changes in cardiac sympathetic innervation post-intervention compared to measurement before intervention by MIBG in a subset of patients
Time Frame: 12 months
|
12 months
|
|
Changes in heart rate variability measures tested by Holter monitoring compared to measurements before the intervention
Time Frame: 12 months
|
12 months
|
|
Changes in biomarkers post intervention representing sympathetic tone compared to before the intervention
Time Frame: 12 months
|
12 months
|
|
Changes in arterial stiffness measures post intervention ambulatory arterial stiffness index by ambulatory blood pressure monitoring, pulse wave velocity and augmentation index compared to measurement before the intervention
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Arif Elvan, MD, PhD, Maatschap Cardiologie Isala
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9206
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Paroxysmal Atrial Fibrillation
-
Medtronic Cardiac Rhythm and Heart FailureCompletedParoxysmal Atrial Fibrillation (PAF)United States, Canada
-
Charite University, Berlin, GermanyGerman Federal Ministry of Education and ResearchTerminatedSymptomatic Paroxysmal Atrial FibrillationGermany
-
Biosense Webster, Inc.RecruitingDrug Refractory Paroxysmal Atrial FibrillationUnited States
-
Biosense Webster, Inc.Active, not recruitingRefractory Paroxysmal Atrial FibrillationChina
-
Boston Scientific CorporationCompletedParoxysmal Atrial Fibrillation (PAF)United States, Spain, Germany, Australia, United Kingdom, Sweden, Czechia, France, Portugal
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Hospital Clinic of BarcelonaCompletedDrug-refractory Paroxysmal Atrial FibrillationSpain
-
Biosense Webster, Inc.CompletedDrug Refractory Symptomatic Paroxysmal Atrial FibrillationUnited States
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Atrial Fibrillation SolutionsCompletedSymptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart DiseasesNetherlands, Australia, France, Norway, Germany, Croatia, Italy, Argentina, Belgium
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
Clinical Trials on procedure
-
NYU Langone HealthCompleted
-
Major Extremity Trauma Research ConsortiumCompleted
-
CathVision ApSTRIQ GROUP Wherry & Klaffke GbRCompletedCardiac ArrhythmiaDenmark, Czechia
-
Virginia Commonwealth UniversityCompletedPersonal Protective EquipmentUnited States
-
Minia UniversityCompletedVisual Impairment | IOP DecreasedEgypt
-
Christiana Care Health ServicesCompletedConsequences of Immunization MethodUnited States
-
Carmen Rosa PallasHospital Universitario 12 de OctubreUnknown
-
Wakayama Medical UniversityRecruitingResectable Pancreatic Body/Tail CarcinomaJapan
-
Assistance Publique Hopitaux De MarseilleRecruiting
-
University Hospital, LilleRecruiting